Mobius® Single-Use Formulation and Fill Solution

Overview

The Mobius® Single-Use Formulation and Fill Solution is a fully integrated, pre-sterilized, single-use platform engineered for aseptic formulation, buffer preparation, and final drug product fill operations in biopharmaceutical manufacturing. Built upon Merck’s proprietary single-use technology architecture, the system operates on a closed, fluid-path-isolated principle—eliminating the need for cleaning-in-place (CIP) and sterilization-in-place (SIP) cycles. Its core design adheres to the principles of process intensification and quality-by-design (QbD), enabling robust control over critical process parameters including flow rate, pressure, temperature, and fill weight accuracy. The Mobius® Fill Solution is not a standalone filler but a modular, scalable system comprising disposable bags (up to 2,000 L), peristaltic or diaphragm pump modules, integrated load cells, sterile connectors, tubing manifolds, and real-time monitoring interfaces—all validated as a cohesive unit. It supports both liquid and lyophilized dosage forms and is routinely deployed in clinical- and commercial-scale manufacturing environments under GMP conditions.

Key Features

• Pre-validated, gamma-irradiated single-use assemblies with full lot traceability and CoA/CoO documentation via Emprove®
• Modular architecture supporting flexible configuration: from benchtop (5–50 L) to production scale (200–2,000 L)
• Integrated gravimetric fill control with ±0.5% fill weight accuracy (at nominal operating range) and real-time deviation alerts
• Biocompatible fluid path materials compliant with USP Class VI, EP 3.1.9, and ISO 10993-5/-10 testing protocols
• Plug-and-play compatibility with major SCADA and MES platforms (e.g., Siemens Desigo, Rockwell FactoryTalk, Dassault DELMIA)
• Onboard data logging with audit trail functionality meeting ALCOA+ and 21 CFR Part 11 requirements

Sample Compatibility & Compliance

The Mobius® Fill Solution accommodates a broad spectrum of biopharmaceutical products—including monoclonal antibodies, recombinant proteins, viral vectors, mRNA-LNPs, and vaccine candidates—without compromising stability or activity. All wetted surfaces are constructed from low-protein-binding, low-particulate polyethylene (PE), ethylene vinyl acetate (EVA), and thermoplastic polyurethane (TPU) films, rigorously tested for extractables under simulated worst-case extraction conditions (per USP ). Each assembly undergoes vendor-supplied E&L profiling; optional BioReliance®-delivered, study-specific E&L reports support regulatory submissions to EMA, PMDA, and FDA. The system meets ISO 13408-1 (aseptic processing), ASTM F2887 (single-use system integrity testing), and ICH Q5A(R2) (viral safety evaluation of cell substrates). Full qualification packages—including Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ)—are available upon request.

Software & Data Management

The Mobius® Fill Solution integrates with Merck’s Mobius® Connect software suite, a Windows-based, GAMP 5-compliant application providing recipe management, batch record generation, electronic signature capture, and automated report export (PDF, CSV, XML). All process data—including fill time, cumulative volume, pump RPM, pressure differentials, and temperature logs—are timestamped, encrypted, and stored locally with optional cloud backup (AWS HIPAA-compliant infrastructure). Audit trails are immutable and reviewable by authorized personnel only; user access levels adhere to role-based permissions (operator, supervisor, QA, admin). Electronic records comply with FDA 21 CFR Part 11, EU Annex 11, and PIC/S PI 011-3 requirements, including electronic signatures with identity verification and reason-for-change annotation.

Applications

• Clinical-phase fill-finish operations for Phase I–III biologics, including cold-chain-sensitive products
• Commercial-scale aseptic filling of vials, syringes, and cartridges under cGMP
• Buffer and media formulation in upstream/downstream purification suites
• Technology transfer between development labs and contract manufacturing organizations (CMOs)
• Rapid deployment for pandemic-response manufacturing (e.g., viral vector or mRNA vaccine fill lines)
• Process validation studies requiring minimal facility modification and reduced utility demand

FAQ

Is the Mobius® Fill Solution suitable for high-viscosity formulations (e.g., >50 cP)?
Yes—when configured with low-shear diaphragm pump modules and optimized tubing geometry, the system handles viscosities up to 200 cP while maintaining fill accuracy and minimizing protein aggregation risk.
Can existing stainless-steel fill lines be retrofitted with Mobius® components?
Yes—Mobius® manifolds and connectors are designed for hybrid integration, enabling seamless transition from fixed to single-use fluid paths without facility revalidation.
Does Merck provide installation and operational support globally?
Yes—Merck offers global field service engineering, IQ/OQ/PQ execution, operator training, and ongoing technical support through certified regional service centers.
How frequently are Emprove® documents updated?
Emprove® documentation is version-controlled and updated quarterly or upon material/process change; all updates are accessible via secure customer portal with revision history and impact assessment notes.
Are Mobius® assemblies compatible with isolator or RABS environments?
Yes—all assemblies meet ISO Class 5 particulate and microbial limits post-sterilization and are routinely deployed inside Grade A isolators with integrated VHP decontamination cycles.